B族链球菌感染致孕母败血症及死胎1例报告

ISSN:2705-098X(P)

EISSN:2705-0505(O)

语言:中文

作者
徐君碧
文章摘要
B族链球菌(group B Streptococcus,GBS)是导致新生儿感染的主要病原体。孕妇消化道和生殖道B族链球菌定植是新生儿早发型GBS病的主要危险因素。GBS在一定状态下可从定植状态转变为致病状态,导致孕妇出现膀胱炎、肾盂肾炎、羊膜腔感染、早产、产后子宫内膜炎、产后脓毒血症及胎儿宫内死亡。本文报道浙江大学医学院附属第四医院收治的1例孕34+周,因GBS感染早产、死胎的患者。现回顾性分析该病例的特点及诊治情况,为临床更好地预防孕妇GBS感染及围产儿GBS病提供借鉴。
文章关键词
妊娠并发症;B族链球菌;败血症;死胎
参考文献
[1] KWATRA G, ADRIAN P V, SHIRI T, et al. Serotype-specific acquisition and loss of group B streptococcus recto-vaginal colonization in late pregnancy [J]. PLoS One, 2014, 9(6): e98778. [2] PHARES C R, LYNFIELD R, FARLEY M M, et al. Epidemiology of invasive group B streptococcal disease in the United States, 1999-2005 [J]. JAMA, 2008, 299(17): 2056-65. [3] SEALE A C, BIANCHI-JASSIR F, RUSSELL N J, et al. Estimates of the Burden of Group B Streptococcal Disease Worldwide for Pregnant Women, Stillbirths, and Children [J]. Clin Infect Dis, 2017, 65(suppl_2): S200-S19. [4] MULLER A E, OOSTVOGEL P M, STEEGERS E A, et al. Morbidity related to maternal group B streptococcal infections [J]. Acta Obstet Gynecol Scand, 2006, 85(9): 1027-37. [5] Prevention of Group B Streptococcal Early-Onset Disease in Newborns: ACOG Committee Opinion Summary, Number 797 [J]. Obstet Gynecol, 2020, 135(2): 489-92. [6] SHABAYEK S, SPELLERBERG B. Group B Streptococcal Colonization, Molecular Characteristics, and Epidemiology [J]. Front Microbiol, 2018, 9(437. [7] RUSSELL N J, SEALE A C, O'DRISCOLL M, et al. Maternal Colonization With Group B Streptococcus and Serotype Distribution Worldwide: Systematic Review and Meta-analyses [J]. Clin Infect Dis, 2017, 65(suppl_2): S100-S11. [8] DING Y, WANG Y, HSIA Y, et al. Systematic Review and Meta-Analyses of Incidence for Group B Streptococcus Disease in Infants and Antimicrobial Resistance, China [J]. Emerg Infect Dis, 2020, 26(11): 2651-9. [9] HUANG J, LIN X Z, ZHU Y, et al. Epidemiology of group B streptococcal infection in pregnant women and diseased infants in mainland China [J]. Pediatr Neonatol, 2019, 60(5): 487-95. [10] 中华医学会围产医学分会, 中华医学会妇产科学分会产科学组. 预防围产期 B 族链球菌病(中国)专家共识 [J]. 中华围产医学杂志, 2021, 24(8): 6. [11] VERANI J R, MCGEE L, SCHRAG S J, et al. Prevention of perinatal group B streptococcal disease--revised guidelines from CDC, 2010 [J]. MMWR Recomm Rep, 2010, 59(RR-10): 1-36. [12] MOKDAD A H, FOROUZANFAR M H, DAOUD F, et al. Global burden of diseases, injuries, and risk factors for young people's health during 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013 [J]. Lancet, 2016, 387(10036): 2383-401. [13] DIGIULIO D B, ROMERO R, AMOGAN H P, et al. Microbial prevalence, diversity and abundance in amniotic fluid during preterm labor: a molecular and culture-based investigation [J]. PLoS One, 2008, 3(8): e3056. [14] HAN Y W, SHEN T, CHUNG P, et al. Uncultivated bacteria as etiologic agents of intra-amniotic inflammation leading to preterm birth[J]. J Clin Microbiol, 2009, 47(1): 38-47. [15] CENTERS FOR DISEASE C, PREVENTION. Perinatal group B streptococcal disease after universal screening recommendations--United States, 2003-2005 [J]. MMWR Morb Mortal Wkly Rep, 2007, 56(28): 701-5. [16] VORNHAGEN J, ADAMS WALDORF K M, RAJAGOPAL L. Perinatal Group B Streptococcal Infections: Virulence Factors, Immunity, and Prevention Strategies [J]. Trends Microbiol, 2017, 25(11): 919-31. [17] KOBAYASHI M, SCHRAG S J, ALDERSON M R, et al. WHO consultation on group B Streptococcus vaccine development: Report from a meeting held on 27-28 April 2016 [J]. Vaccine, 2019, 37(50): 7307-14. [18] MELIN P, EFSTRATIOU A. Group B streptococcal epidemiology and vaccine needs in developed countries [J]. Vaccine, 2013, 31 Suppl 4(D31-42. [19] DONDERS G G, HALPERIN S A, DEVLIEGER R, et al. Maternal Immunization With an Investigational Trivalent Group B Streptococcal Vaccine: A Randomized Controlled Trial [J]. Obstet Gynecol, 2016, 127(2): 213-21. [20] HEYDERMAN R S, MADHI S A, FRENCH N, et al. Group B streptococcus vaccination in pregnant women with or without HIV in Africa: a non-randomised phase 2, open-label, multicentre trial [J]. Lancet Infect Dis, 2016, 16(5): 546-55. [21] KOBAYASHI M, VEKEMANS J, BAKER C J, et al. Group B Streptococcus vaccine development: present status and future considerations, with emphasis on perspectives for low and middle income countries [J]. F1000Res, 2016, 5(2355.
Full Text:
DOI